Editas medicine Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Editas medicine Contact Number

Contact Us Editas Medicine

9 hours ago Editasmedicine.com Show details

(617) 401-9000BOULDER, CO 4909 Nautilus Court North Suite 208/211 Boulder, CO 80301 +-

1. 11 Hurley St, Cambridge, MA 02141 · (617) 401-9000DIRECTIONSWEBSITE

Category: Contact SupportShow more

Editas Medicine

1 hours ago Editasmedicine.com Show details

At Editas Medicine, we are using this technology to develop transformative and durable medicines for people living with serious diseases. The People We Serve We are motivated to deliver transformative medicines to the greatest number of patients around the world.

Category: Contact NumberShow more

Editas Medicine, Inc. Company Profile Cambridge, MA

3 hours ago Dnb.com Show details

Find company research, competitor information, contact details & financial data for Editas Medicine, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.

Employees: 89
Total Assets: $572.6
Tangible Fixed Assets: $39.15
Location: 11 Hurley St, Cambridge, 02141-2110, MA

Category: Contact NumberShow more

Editas Medicine 4909 Nautilus Ct N Boulder, CO

2 hours ago Mapquest.com Show details

(303) 997-7553Editas Medicine 4909 Nautilus Ct N Boulder, CO Nonclassified Establishments - MapQuest. Editas Medicine. 4909 Nautilus Ct N. Boulder CO 80301. Reviews. (303) 997-7553 Website. Menu & Reservations.

Category: Contact NumberShow more

Editas Medicine Company Profile Office Locations

2 hours ago Craft.co Show details

Editas Medicine has 208 employees across 3 locations and $90.73 M in annual revenue in FY 2020. See insights on Editas Medicine including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Employees: 208
Revenue (Q1, 2021): 6.5m
Founded: 2013
Type: Public

Category: Contact NumberShow more

Investor FAQs Editas Medicine

3 hours ago Ir.editasmedicine.com Show details

617-401-9000Investor FAQs. Where is Editas headquartered? Our headquarters are located at 11 Hurley Street, Cambridge, MA 02141. The main office number is 617-401-9000.

Category: Contact NumberShow more

Editas Medicine Corporate Headquarters, Office Locations

2 hours ago Craft.co Show details

Editas Medicine has 2 office locations across 1 country. See the full list at Craft.

Category: Contact NumberShow more

Editas Medicine Company Profile: Stock Performance

7 hours ago Pitchbook.com Show details

Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9

Category: Contact NumberShow more

Editas Medicine, Inc. (EDIT) Company Profile & Overview

6 hours ago Stockanalysis.com Show details

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in

Category: Contact NumberShow more

EDIT301 for Autologous HSCT in Subjects With Severe

7 hours ago Clinicaltrials.gov Show details

Information from the National Library of Medicine. To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier …

Category: Contact NumberShow more

Here’s Why Editas Medicine Inc. (NASDAQ: EDIT) Is A Good

3 hours ago Stocksregister.com Show details

The number of analysts that have assigned EDIT a recommendation rating is 16. Out of them, 5 rate it a Hold, while 7 recommend Buy, whereas 1 assign an Overweight rating. 0 analyst(s) have tagged Editas Medicine Inc. (EDIT) as Underweight, while 3 advise Sell.

Category: Contact NumberShow more

Editas Medicine Flagship Pioneering

1 hours ago Flagshippioneering.com Show details

Editas, founded in 2013, is a leading genome editing company and part of a transformational new area of health care – genomic medicine. The company was founded by the pioneers and world leaders in genome editing to translate the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of …

Category: Contact NumberShow more

Hedge Funds Are Selling Editas Medicine, Inc. (EDIT

1 hours ago Insidermonkey.com Show details

The number of long hedge fund bets shrunk by 1 in recent months. Editas Medicine, Inc. (NASDAQ:EDIT) was in 23 hedge funds’ portfolios at the end of the second quarter of 2021. The all time high

Category: Contact NumberShow more

Editas Overview, News & Competitors ZoomInfo.com

6 hours ago Zoominfo.com Show details

Description. Editas Medicine is a genome editing company focused on translating the power and potential of genome editing systems into a pipeline of medicines for people liv Read More. Headquarters: 11 Hurley St, Cambridge, Massachusetts, 02141, United States.

Category: Contact NumberShow more

Editas Medicine Wikipedia

5 hours ago En.wikipedia.org Show details

Total equity. US$262,437,000 (2019) Number of employees. 208 (2020) Website. www .editasmedicine .com. Editas Medicine (formerly Gengine, Inc.) is a clinical-stage biotechnology company which is developing therapies based on CRISPR–Cas9 gene editing technology. Editas is based in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

Category: Contact NumberShow more

Editas Medicine Employees, Board Members, Advisors & Alumni

2 hours ago Crunchbase.com Show details

Editas Medicine has 16 current employee profiles, including Senior Vice President & Chief Legal Officer Charlene Stern. Charlene Stern Senior Vice President & Chief Legal Officer. Kevin Bitterman Interim President. James Mullen Chairman, President, and CEO. Mark S.Shearman Chief Scientific Officer & Executive Vice-President.

Category: Contact NumberShow more

$EDIT: New data is out now for Editas Medicine Inc – The

8 hours ago Wallstreetfacts.com Show details

The 52-week high for Editas Medicine Inc is $99.95 and the low is $27.12. We will be moving onto the number of outstanding shares. One is that you can use shares outstanding to calculate the market capitalization, the total value, of a corporation.

Category: Contact NumberShow more

Edward Goncz Principal Research Associate Editas

6 hours ago Apollo.io Show details

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable …

Category: Contact NumberShow more

Editas Medicine Funding, Financials, Valuation & Investors

4 hours ago Crunchbase.com Show details

Editas Medicine has raised a total of $656.6M in funding over 5 rounds. Their latest funding was raised on Jan 21, 2021 from a Post-IPO Equity round. Editas Medicine is registered under the ticker NASDAQ:EDIT . Their stock opened with $16.00 in its Feb 3, 2016 IPO. Editas Medicine is funded by 17 investors.

Category: Contact NumberShow more

Editas Medicine Stock price prediction (NASDAQ:EDIT)

4 hours ago Macroaxis.com Show details

Editas Medicine Quick Ratio is comparatively stable at the moment as compared to the past year. Editas Medicine reported Quick Ratio of 7.01 in 2020. Asset Turnover is likely to gain to 0.17 in 2021, whereas Net Current Assets as percentage of …

Category: Contact NumberShow more

Editas Medicine Announces Pricing of Initial Public

2 hours ago Ir.editasmedicine.com Show details

(973) 271-6085About Editas Medicine the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients. Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact

Category: Contact NumberShow more

Hedge Funds Are Selling Editas Medicine, Inc. (EDIT)

1 hours ago Finance.yahoo.com Show details

The number of long hedge fund bets shrunk by 1 in recent months. Editas Medicine, Inc. (NASDAQ: EDIT) was in 23 hedge funds' portfolios at the end of the second quarter of 2021. The all time high

Category: Contact NumberShow more

Insiders in Editas Medicine, Inc. (NASDAQ:EDIT) are down

1 hours ago Finance.yahoo.com Show details

Some of the losses seen by insiders who purchased US$1.4m worth of Editas Medicine, Inc. (NASDAQ:EDIT) shares over the past year were recovered after the stock increased by 6.8% over the past week

Category: Contact NumberShow more

Why Editas Medicine Stock Is Jumping Today Nasdaq

4 hours ago Nasdaq.com Show details

What happened Shares of Editas Medicine (NASDAQ: EDIT) were jumping 9.4% as of 12:27 p.m. EST on Monday. The gain came after the company provided its third-quarter update earlier in the day.

Category: Contact NumberShow more

After long wait, Editas reveals first data for CRISPR gene

3 hours ago Biopharmadive.com Show details

The data, announced by Editas and set to be presented at a medical conference Wednesday, offer some hopeful signs the company's therapy could help treat an inherited form of vision loss. But the small number of patients involved, as well as the limited follow-up afterwards, make the results difficult to interpret.

Category: Contact NumberShow more

Editas Medicine and Azzur Group Announce a Multiyear

5 hours ago Globenewswire.com Show details

Editas Medicine will utilize the space and Azzur’s services to execute pre-clinical and early-phase clinical manufacturing activities for …

Category: Contact NumberShow more

Is Editas Medicine Inc. (NASDAQ: EDIT) Expensive At $36.72

3 hours ago Marketingsentinel.com Show details

1. Looking at statistics comparing Editas Medicine Inc. share performance against respective industry, we note that the company has underperformed competitors. Editas Medicine Inc. (EDIT) shares are 3.18% up over the last 6 months, with its year-to-date growth rate lower than industry average at -79.29% against 7.40%. Revenue is forecast to shrink -783.30% this quarter before jumping 13.00% for the next one. The rating firms project that company’s revenue will shrink -79.00% compared to the previous financial year. Revenue forecast for the current quarter as set by 10 analysts is $5.67 million. Meanwhile, for the quarter ending Dec 2021, a total of 10 analyst(s) estimate revenue growth to $6.79 million.Earnings reports from the last fiscal year show that sales brought in $62.84 million and $11.42 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -91.00% before dropping -40.50% in the following quarter.

Category: Contact NumberShow more

Editas Medicine Number of Employees 20152021 EDIT

2 hours ago Macrotrends.net Show details

Editas Medicine number of employees from 2015 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis

Category: Contact NumberShow more

Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating

1 hours ago Marketbeat.com Show details

Shares of Editas Medicine stock opened at $32.37 on Friday. The firm has a market capitalization of $2.21 billion, a P/E ratio of -9.99 and a beta of 1.97. Editas Medicine has a 12 month low of $29.35 and a 12 month high of $99.95. The business has a fifty day simple moving average of $40.43 and a two-hundred day simple moving average of $45.05

Category: Contact NumberShow more

Brokerages Anticipate Editas Medicine, Inc. (NASDAQ:EDIT

7 hours ago Marketbeat.com Show details

Wall Street analysts expect Editas Medicine, Inc. (NASDAQ:EDIT) to post ($0.82) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Editas Medicine's earnings, with estimates ranging from ($1.16) to ($0.65). Editas Medicin

Category: Contact NumberShow more

Katrine Bosley Net Worth, Biography & Insider Trading History

1 hours ago Insidertrades.com Show details

(617) 401-9000The corporate mailing address for Ms. Bosley and other Editas Medicine executives is 11 Hurley Street, Cambridge MA, 02141. Editas Medicine can also be reached via phone at (617) 401-9000 and via email at mark[email protected]

Category: Contact NumberShow more

Editas Medicine Announces Positive Initial Clinical Data

9 hours ago Globenewswire.com Show details

Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 September 29, 2021 09:00 ET Source: Editas Medicine, Inc. Editas

Category: Contact NumberShow more

Editas Medicine Beats Earnings Whispers

8 hours ago Earningswhispers.com Show details

Editas Medicine (EDIT) reported a 3rd Quarter September 2021 loss of $0.57 per share on revenue of $6.2 million. The consensus estimate was a loss of $0.86 per share on revenue of $4.8 million. The Earnings Whisper number was for a loss of $0.87 per share. Revenue fell 90.1% compared to the same quarter a year ago.

Category: Contact NumberShow more

EDITAS MEDICINE, INC. : EDIT Stock Price US28106W1036

2 hours ago Marketscreener.com Show details

Editas Medicine, Inc. is a clinical-stage gene editing company. The Company is focused on developing transformative gene-editing medicines to treat a range of serious diseases. It operates through the developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly

Category: Contact NumberShow more

Editas Medicine (EDIT) Appoints Bernadette Connaughton to

9 hours ago Streetinsider.com Show details

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has appointed Bernadette Connaughton to its Board of Directors. Ms. Connaughton is an accomplished

Category: Contact NumberShow more

Editas Medicine : Oppenheimer Upgrades Editas Medicine to

3 hours ago Marketscreener.com Show details

October 14, 2021. Editas Medicine : Oppenheimer Upgrades Editas Medicine to Outperform From Perform, Adjusts PT to $80 From $42

Category: Contact NumberShow more

Analyst Ratings For Editas Medicine Editas Medicine

1 hours ago Benzinga.com Show details

In the last 3 months, 5 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $65.2 with a high of $80.00 and a low of $41.00. Below is a

Category: Contact NumberShow more

Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue

1 hours ago Nasdaq.com Show details

Editas Medicine (EDIT) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $0.12 per share a year ago. These

Category: Contact NumberShow more

EDIT Editas Medicine Inc. Company Profile & Executives WSJ

8 hours ago Wsj.com Show details

Company Info Editas Medicine Inc. 11 Hurley Street. Cambridge Massachusetts 02141. United States. Website. Map. Employees 235. Sector Biotechnology. Sales or Revenue 90.73 M.

Category: Contact NumberShow more

Editas Medicine, Inc., Jobs & Salary for Foreign Workers

7 hours ago Myvisajobs.com Show details

Editas Medicine, Inc. has filed 23 labor condition applications for H1B visa and 2 labor certifications for green card from fiscal year 2018 to 2020. Editas Medicine was ranked 8780 among all visa sponsors. Please note that 0 LCA for H1B Visa and 0 LC for green card have been denied or withdrawn during the same period.

Category: Contact NumberShow more

Will Editas Medicine Inc. (EDIT) Future Potential Be

Just Now Marketingsentinel.com Show details

Editas Medicine Inc. (NASDAQ:EDIT)’s Major holders. Insiders own 0.25% of the company shares, while shares held by institutions stand at 75.79% with a share float percentage of 75.98%. Investors are also buoyed by the number of investors in a company, with Editas Medicine Inc. having a total of 416 institutions that hold shares in the company.

Category: Contact NumberShow more

Editas Stock Price EDIT 35.35 0.92 (2.5364999999999998%)

2 hours ago Macroaxis.com Show details

Editas Medicine is selling for under 35.35 as of the 22nd of November 2021; that is -2.54 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 35.06. Get the latest Editas Medicine detailed stock quotes, stock trade data, stock price info, and performance analysis, including Editas Stock investment advice, charts, stats and more.

Category: Contact NumberShow more

Editas Medicine LinkedIn

8 hours ago Linkedin.com Show details

Editas Medicine 22,923 followers on LinkedIn. What If You Could Repair Broken Genes? What if you could repair broken genes? That is the question we …

Category: Contact NumberShow more

Analysts Estimate Editas Medicine (EDIT) to Report a

2 hours ago Zacks.com Show details

Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for. Zacks Equity Research November 01, 2021 EDIT Quick Quote EDIT. Trades from $ 1

Category: Contact NumberShow more

Premarket Mover: Editas Medicine Inc (EDIT) Up 2.06%

Just Now Investorsobserver.com Show details

In the Biotechnology industry which is number 131 by this metric, EDIT ranks better than 84% of stocks. Important Dates for Investors in EDIT:-Editas Medicine Inc is set to release earnings on 11/2/2021. During their last earnings release the company posted EPS of $-2.60. -We do not have a set dividend date for Editas Medicine Inc at this time.

Category: Contact NumberShow more

Should You Accumulate Editas Medicine Inc (EDIT) Stock

9 hours ago Investorsobserver.com Show details

In the Biotechnology industry which is number 132 by this metric, EDIT ranks better than 73% of stocks. Important Dates for Investors in EDIT:-Editas Medicine Inc is set to release earnings on 11/2/2021. During their last earnings release the company posted EPS of $-2.60. -We do not have a set dividend date for Editas Medicine Inc at this time.

Category: Contact NumberShow more

Cathie Wood’s Top 5 SmallCap Stock Picks Insider Monkey

7 hours ago Insidermonkey.com Show details

Number of Hedge Fund Holders: 23. Ranking first on our list of Cathie Wood’s top 15 small-cap stock picks is Editas Medicine, Inc. (NASDAQ:EDIT), which is a biotechnology company focused on

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What happened to the CEO of Editas Medicine?

CEO Katrine Bosley stepped down in 2019 and was replaced by board member Cynthia Collins. Also in 2019, the company was building new chemistry facilities in Boulder, Colorado. In January 2020, Editas Medicine appointed Michelle Robertson as the company's Chief Financial Officer.

What is editeditas Medicine Inc (edit)?

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment.

How much assets does Editas Medical Group have?

Type Public Total assets US$508,885,000 (2019) Total equity US$262,437,000 (2019) Number of employees 208 (2020) Website www .editasmedicine .com 6 more rows ...

What is the target price for Editas Medicine?

EDITAS MEDICINE : Oppenheimer Sets $42 Price Target for Editas Medicine, Reitera.. EDITAS MEDICINE : Management's Discussion and Analysis of Financial Condition an..

Popular Brands

Essity
Engie
Eaton